Skip to main content

Polymyalgia Rheumatica

7
Pipeline Programs
6
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 7 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
2
SecukinumabPhase 3Monoclonal Antibody1 trial
Secukinumab 300 mgPhase 31 trial
AIN457Phase 21 trial
Active Trials
NCT01364389Terminated16Est. Jan 2013
NCT06331312Active Not Recruiting161Est. Aug 2028
NCT05767034Completed381Est. Feb 2026
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
SirukumabPhase 3Monoclonal Antibody
Sparrow Pharmaceuticals
2 programs
1
1
SPI-62Phase 21 trial
PrednisolonePhase 11 trial
Active Trials
NCT06281236Terminated1Est. Apr 2025
NCT05436652Completed66Est. Apr 2025
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ABBV-154Phase 21 trial
Active Trials
NCT04972968Terminated181Est. Jul 2023
Chugai Pharma
Chugai PharmaJapan - Tokyo
2 programs
TCZPHASE_21 trial
TocilizumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT01713842Completed21Est. Oct 2014
NCT02908217Completed113Est. Nov 2020
Regeneron
RegeneronTARRYTOWN, NY
1 program
Sarilumab SAR153191PHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
SandozSecukinumab
SandozSecukinumab 300 mg
Chugai PharmaTocilizumab
Sparrow PharmaceuticalsSPI-62
AbbVieABBV-154
Chugai PharmaTCZ
SandozAIN457
Sparrow PharmaceuticalsPrednisolone

Clinical Trials (8)

Total enrollment: 940 patients across 8 trials

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Start: Jun 2024Est. completion: Aug 2028161 patients
Phase 3Active Not Recruiting
NCT05767034SandozSecukinumab 300 mg

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Start: Mar 2023Est. completion: Feb 2026381 patients
Phase 3Completed

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Start: Feb 2017Est. completion: Nov 2020113 patients
Phase 3Completed

A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

Start: Jul 2022Est. completion: Apr 202566 patients
Phase 2Completed

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

Start: Sep 2021Est. completion: Jul 2023181 patients
Phase 2Terminated

Tocilizumab Effect iN pOlymyalgia Rheumatica

Start: Jul 2012Est. completion: Oct 201421 patients
Phase 2Completed

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Start: Feb 2011Est. completion: Jan 201316 patients
Phase 2Terminated

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

Start: Feb 2022Est. completion: Apr 20251 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.